The Role of Fluoxetine and Selective Serotonin Re-uptake Inhibitors in Motor Recovery Following Acute Ischaemic Stroke

François Chollet,¹ Jean Tardy,² Jérémie Pariente,¹ Isabelle Loubinoux¹ and Jean-François Albucher²

¹. Professor; 2. Physician Neurologist; 3. Assistant Professor; 4. Researcher in Neuroscience, Department of Neurology, Purpan University Hospital, INSERM U825, Paul Sabatier University Toulouse III

Abstract

Until now, recombinant tissue plasminogen activator thrombolysis within the first hours after a stroke has been recognised as the only validated treatment able to improve the spontaneous – and most of the time incomplete – recovery of neurological functions after stroke. However, we have learnt from research over the last decade, in part based on the considerable improvement in neuroimaging techniques, that spontaneous recovery of neurological functions was associated with a large intracerebral re-organisation of the damaged human brain. The question of whether lesioned-brain plasticity can be modulated by external factors such as pharmacological agents is now addressed, with the aim of improving recovery and reducing the final disability of patients. We review the preclinical and clinical arguments for a direct action of selective serotonin re-uptake inhibitors in promoting recovery after stroke in humans.

Keywords

Stroke, recovery, fluoxetine, brain plasticity, motor function, monoaminergic drugs

Disclosure: The authors have no conflicts of interest to declare.

Received: 2 September 2011 Accepted: 21 November 2011 Citation: European Neurological Review, 2011;6(4):249–53 DOI:10.17925/ENR.2011.06.04.249

Correspondence: François Chollet, Department of Neurology, Purpan University Hospital and Paul Sabatier University, Place Baylac, 31059 Toulouse, France. E: francois.chollet@inserm.fr

Recovery of neurological functions after a stroke has long been a puzzling question for clinicians and scientists. On the one hand, clinicians knew from their own practice that partial recovery was very often observed after a stroke and on the other hand, it was well known that neurons, when destroyed after ischaemia, were not restored despite some very localised neurogenesis. In the past two decades, we have learnt from modern neuroimaging techniques, mainly positron emission tomography (PET) scanning and magnetic resonance imaging (MRI), that the human brain is able to spontaneously re-organise after a stroke and that brain re-organisation can be considered as a rational biological basis for recovery of neurological functions. The question of whether lesioned-brain plasticity can be modulated by external factors such as pharmacological agents is now addressed with the aim of improving recovery and reducing the final disability of patients. Preclinical studies, mainly using small animal models, have shown that monoaminergic drugs can modify functional recovery. This is particularly the case for noradrenergic drugs, which have been shown to improve functional recovery, while neuroleptics have been shown to impair it. From this approach, selective serotonin re-uptake inhibitors (SSRIs) were tested and their suspected positive action in the recovery process was recently proved in the Fluoxetine for motor recovery after acute ischaemic stroke (FLAME) trial.

Preclinical Arguments for Direct Action of Monoaminergic Drugs on the Damaged Brain

Studies in laboratory animals clearly show that the rate and extent of functional recovery after focal brain injury can be modulated by drugs affecting certain neurotransmitters in the central nervous system (CNS). Several lines of evidence suggest that motor recovery after injury to the cerebral cortex can be modulated through the effects of norepinephrine on the CNS. For example, in rats, central infusion of norepinephrine hastens locomotor recovery after a unilateral sensorimotor cortex lesion. In contrast, the administration of DSP-4 [N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine], a neurotoxin that leads to the depletion of norepinephrine in the CNS, has the opposite effect and delays the recovery process. In addition, bilateral or unilateral selective lesions of the locus ceruleus, the major source of noradrenergic projection fibres to the cerebral cortex and cerebellum, also impair motor recovery after a subsequent unilateral cortical lesion. Dopaminergic agents also act in damaged brains. They may influence recovery from neglect caused by prefrontal cortical injury. Apomorphine, a dopamine agonist, reduces the severity of experimentally induced neglect, and spiroperidol, a dopamine receptor antagonist, reinstates neglect in recovered animals. Concurrent administration of dopamine-blocking drugs such as haloperidol also blocks amphetamine-promoted recovery and haloperidol, as well as other butyrophenones (fluanisone, droperidol), transiently reinstates the deficits in recovered animals.¹⁴

The role of antidepressant SSRIs was initially more controversial. Some studies detected little or no significant action on recovery. However, more recent studies have underlined that fluoxetine is active in rat stroke models. Fluoxetine reduces the size of the infarcted zone and demonstrates a strong neuroprotective action through its anti-inflammatory action. Moreover, fluoxetine has been shown to improve
Brain Trauma  Stroke

Table 1: Reported Prospective Randomised Placebo-controlled Clinical Trials of Selective Serotonin Re-uptake Inhibitors in Motor Recovery After Ischaemic Stroke

<table>
<thead>
<tr>
<th>Study</th>
<th>Drug(s)</th>
<th>Dose, Regimen and Treatment Duration</th>
<th>n</th>
<th>Trial Design</th>
<th>Time of Inclusion After Stroke</th>
<th>Clinical Outcome Criteria</th>
<th>Other Outcome Criteria</th>
<th>Patients in Rehabilitation Programme</th>
<th>Main Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dam, et al.</td>
<td>Fluoxetine and maprotiline</td>
<td>Fluoxetine 20 mg once a day for 90 days</td>
<td>48</td>
<td>Parallel groups (three groups)</td>
<td>1–6 months</td>
<td>Graded neurological scale (HSS)</td>
<td>None</td>
<td>Yes</td>
<td>10.7 % improvement in HSS scores</td>
</tr>
<tr>
<td>Pariente, Fluoxetine et al.</td>
<td>Fluoxetine</td>
<td>20 mg (single dose)</td>
<td>8</td>
<td>Cross-over</td>
<td>15–30 days</td>
<td>Finger tapping and dynamometer</td>
<td>Functional MRI; hyperactivation of motor cortices</td>
<td>Yes</td>
<td>20–30 % finger tapping and dynamometer improvement</td>
</tr>
<tr>
<td>Zittel, et al.</td>
<td>Citalopram</td>
<td>40 mg (single dose)</td>
<td>8</td>
<td>Cross-over</td>
<td>More than 6 months</td>
<td>Motor dexterity with nine-hole-peg test</td>
<td>None</td>
<td>Yes</td>
<td>11.4 % improvement in nine-hole-peg test</td>
</tr>
<tr>
<td>Acler, et al.</td>
<td>Citalopram</td>
<td>10 mg once a day for 30 days</td>
<td>20</td>
<td>Parallel groups (two groups)</td>
<td>NR</td>
<td>NIHSS score</td>
<td>TMS; modulation of cortical excitability</td>
<td>Yes</td>
<td>38.8 % improvement in NIHSS scores</td>
</tr>
</tbody>
</table>

HSS = Hemispheric Stroke Scale; MRI = magnetic resonance imaging; NIHSS = National Institutes of Health Stroke Scale; NR = not reported.

Results of all trials showed positive effect on motor performance. Results of a randomised placebo-controlled trial by Gerdelat-Mas et al. in healthy individuals also confirmed the modulation of cortical excitability induced by transcranial magnetic stimulation (TMS) with a single and chronic doses of paroxetine.

Figure 1: Improvement of Motor Performance and Hyperactivation of Primary Motor Cortex (S1M1) After a Single Dose of 20 mg Fluoxetine in Eight Recovering Stroke Patients Compared with Placebo

that, with increasing dose, amphetamine brings increasing then decreasing benefit.

Fourth, the timing of drug administration may be crucial. A therapeutic time window probably exists.

Last, the effects of many drugs are highly dependent on experimental details. For example, drug infusion paired with behavioural training does not have the same behavioural effect as the drug infusion without training.

**Monoaminergic Drugs and Motor Recovery After Stroke**

Many monoaminergic drugs have been tested in small or middle-sized clinical trials in patients with stroke. Amphetamines were probably the most studied, including a total of 287 patients. Only the first two studies were able to demonstrate beneficial effects. Walker-Batson et al. administered 10 mg D-amphetamine every fourth day, coupled with physiotherapy. Changes in motor performance were evaluated with the Fugl-Meyer Motor Scale (FMMS). Subsequent studies failed to show a superiority of D-amphetamine compared with placebo, even though some of these studies used the same protocols as one of the early intervention studies. A recent review summarised that it is currently impossible to draw any definite conclusions about the potential role of D-amphetamine in motor rehabilitation. Methylphenidate produces an increase in dopamine signalling through multiple actions. A prospective, randomised, double-blind, placebo-controlled trial with 21 patients early after stroke indicated that the combination of methylphenidate with physiotherapy over a period of three weeks improved motor function (as measured by the FMMS and a modified version of the Functional Independence Measure) and decreased depression. A subsequent neuroimaging study by Tardy et al. confirmed these findings.

Levodopa gave conflicting results both in single-dose and in repeated-dose trials. A randomised study with stroke patients (n=53) six weeks after stroke onset demonstrated that 100 mg levodopa given once a day over a period of three weeks in combination with carbidopa was significantly better than placebo in reducing motor deficits as measured by the Rivermead Motor Assessment. The improvement persisted over the subsequent three weeks. However, the study results have not been replicated by others up to now and a recent study with subacute stroke patients who received 100 mg levodopa per day for two weeks did not find a stronger improvement of motor functions than in the group treated with placebo.

Cognitive deficits in rats and to stimulate neurogenesis. From published experimental studies, several main conclusions can be emphasised that have been used in developing SSRI fluoxetine clinical trials.

- First, these studies provide convincing evidence that there is obviously a large interaction between certain drugs and the recovery process in animal models. Norepinephrine and its agonists and antagonists have probably been the most studied drugs but others with potentially fewer side effects, such as SSRIs, could be expected to be beneficial.
- Second, it appears that the cellular mechanisms underlying these significant effects of drugs acting on the CNS is beginning to be better understood. Additional basic research is needed to further investigate such pharmacological actions in the setting of rewiring and cellular growth in the damaged brain.
- Third, drugs can have varying effects according to the dosage and also the dose regimen. For example, animal studies have found...
Very little is known about the mechanism of action of piracetam, but there is some evidence that it enhances glucose utilisation and cellular metabolism in the brain. A Cochrane Review concluded that “treatment with piracetam may be effective in the treatment of aphasia after stroke.”

Other drugs, such as reboxetine, an inhibitor of the re-uptake of norepinephrine, moclobemide, an inhibitor of monoamine oxidase A, and donepezil, an inhibitor of acetylcholinesterase, have been tested in small series with variable results, which prevent any conclusion being drawn on their efficacy.2,3

Until now, there has been only limited evidence supporting or refuting the use of centrally acting drugs to enhance the effects of neurorehabilitation. Many reasons have been given to explain the difficulties encountered by the investigators: small number of patients, recruitment of patients (25–40 screened for one enrolled), heterogeneity in stroke types, sizes and locations of lesions, concomitant neurological symptoms (within-subject variability in recovery), standardisation of rehabilitation programmes, dose of the drug, specific chemical formulation of the drug under study (D- or DL-amphetamines), time of prescription, duration of treatment, etc. The interpretation is further complicated by conflicting results and the occurrence of side effects (noradrenergic drugs).

Selective Serotonin Re-uptake Inhibitors and Stroke

Stroke and Depression

Post-stroke depression (PSD) is a common disorder, affecting 30–50% of hemiplegic patients within one year of their cerebral infarction. In the early stage, i.e. during the first three to four months after a stroke, PSD poses serious problems, such as worsened functional and vital prognoses as well as worsened quality of life of the patient and carer. In this context, however, SSRIs were first used as antidepressants and were tested in humans in PSD.

Selective Serotonin Re-uptake Inhibitors as a Treatment for Depressed Stroke Patients

Sixteen trials (17 interventions), with 1,655 participants, were included in a recent Cochrane review. Data were available for 13 pharmaceutical agents. There was some evidence of the benefit of pharmacotherapy in terms of a complete remission of depression and a reduction (improvement) in scores on depression rating scales, but there was also evidence of an associated increase in adverse events. From those series, two studies with the SSRI fluoxetine showed a benefit in depressed patients (Fruehwald et al. and Wiart et al.).20–24

Selective Serotonin Re-uptake Inhibitors Probably Also Prevent Post-stroke Depression

Fourteen trials involving 1,515 participants were included in a recent Cochrane review. Data were available for 10 pharmaceutical trials (12 comparisons) with different antidepressants. There was no clear global effect of pharmacological therapy on the prevention of depression. However, arguments exist for a positive effect of citalopram.20–27

Selective Serotonin Re-uptake Inhibitors and Motor Recovery After Stroke

Small Trials

Few clinical trials with serotonin re-uptake inhibitors have been reported (see Table 1).28–31 They have all included small numbers of patients; all have results that suggest a positive effect on recovery after stroke. In an early trial, fluoxetine and maprotiline were tested against placebo for three months in patients with hemiplegic stroke enrolled one to six months after the stroke. The patients in the fluoxetine group (n=16) had a better outcome than those in the maprotiline or placebo groups.20 Acler et al. confirmed this finding in ten patients in the active-treatment group versus ten in the placebo group.21 In a double-blind, placebo-controlled cross-over trial, Zittel et al. investigated the effects of a single dose (40 mg) of citalopram in patients with chronic stroke.22 Dexterity was significantly improved.

Proof of Concept

In a double-blind placebo-controlled study by our group, Pariente et al., by combining clinical motor testing and functional MRI motor assessment in patients recovering from post-stroke hemiplegia (n=8), showed that a single dose (20 mg) of fluoxetine improved hand motor function and was correlated with an overactivation of motor cortices on functional MRI (see Figure f).23 In a subsequent double-blind, placebo-controlled trial in healthy individuals, transcranial magnetic stimulation showed that the intake of a single dose of the serotonín re-uptake inhibitor paroxetine was associated with hypereexcitability of the primary motor cortex, whereas chronic intake was associated with hypoexcitability of the brain motor cortices. Serotonin re-uptake inhibition with fluoxetine...
Chollet A4_2011 22/12/2011 14:28 Page 252

17. Restemeyer C, Weiller C, Liepert J, No effect of a levodopa

Fluoxetine for Motor Recovery After Acute Ischaemic Stroke (FLAME) Trial – Distribution of Modified Rankin Scale Scores at Day 90

Fluoxetine (n=57) Placebo (n=56)

<table>
<thead>
<tr>
<th>Score</th>
<th>Fluoxetine (n=57)</th>
<th>Placebo (n=56)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1 (2 %)</td>
<td>2 (3 %)</td>
</tr>
<tr>
<td>1</td>
<td>12 (21 %)</td>
<td>7 (12 %)</td>
</tr>
<tr>
<td>2</td>
<td>18 (32 %)</td>
<td>15 (26 %)</td>
</tr>
<tr>
<td>3</td>
<td>21 (37 %)</td>
<td>26 (46 %)</td>
</tr>
<tr>
<td>4</td>
<td>7 (12 %)</td>
<td>10 (17 %)</td>
</tr>
<tr>
<td>5</td>
<td>6 (10 %)</td>
<td>4 (7 %)</td>
</tr>
</tbody>
</table>

Source: Chollet et al., 2011.

In this double-blind, placebo-controlled trial, patients from nine stroke centres who had suffered an ischaemic stroke, had hemiplegia or hemiparesis, had FMMS scores of 55 or less and were aged between 18 and 85 years were eligible for inclusion. Patients with depression were excluded. Patients were randomly assigned, using a computer random-number generator, in a 1:1 ratio, to fluoxetine (20 mg once per day, orally) or placebo for three months starting five to 10 days after the onset of stroke. All patients had physiotherapy. The primary outcome measure was the change on the FMMS between day 0 and day 90 after the start of the study drug. Participants, carers and physicians assessing the outcome were masked to group assignment. Analysis was of all patients for whom data were available (full analysis set). One hundred and eighteen patients were randomly assigned to fluoxetine (n=59) or placebo (n=59), and 113 were included in the analysis (57 in the fluoxetine group and 56 in the placebo group). Two patients died before day 90 and three withdrew from the study.

FMMS improvement at day 90 was significantly greater in the fluoxetine group (adjusted mean 34.0 points [95 % confidence interval (CI) 29.7–38.4]) than in the placebo group (24.3 points [95 % CI 19.9–28.7]; p=0.003). The drug was well tolerated. Moreover, the number of independent patients (modified Rankin scale [mRS] 0–2 after three months of treatment) was higher in the fluoxetine group. The number of depressions occurring during the three-month treatment period was lower in the fluoxetine group.

The mechanism of action of fluoxetine needs to be discussed. An effect of fluoxetine on mood is likely even in non-depressed people. However, we do not think that fluoxetine acted only through antidepressant mechanisms in this study. As mentioned above, a single dose of fluoxetine improved hand motor function and increased activity in the motor cortex compared with placebo in patients with stroke, showing a specific motor effect, whereas a mood effect is unlikely after a single dose. However, a fluoxetine-mediated attention and/or a fluoxetine-mediated motivation effect cannot be excluded and needs to be investigated in further studies.

Nevertheless, the FLAME trial has limitations. The number of patients included was small. Those who were included were selected for motor deficit and did not represent the general population of stroke patients. Secondly, treatment was stopped after 90 days and we have no idea of the long-term development of patients’ motor function and whether the treatment effect persisted in the months after treatment was stopped. However, the effect of fluoxetine seems to be strong and clinically relevant, and the data of the trial show a global coherence.

In patients with ischaemic stroke and moderate to severe motor deficit, the early prescription of fluoxetine with physiotherapy led to enhanced motor recovery after three months. Modulation of spontaneous brain plasticity by drugs is a promising pathway for treatment of patients with ischaemic stroke and moderate to severe motor deficit.

It is still fair to estimate that no regulatory agency will grant approval for use of such drugs until evidence is also provided by properly powered, formal phase III clinical trials including a larger number of patients whose characteristics are more similar to those of the general population of patients with stroke. Such trials would probably have to evaluate effects in the long term.


